JP2019509055A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509055A5
JP2019509055A5 JP2018555841A JP2018555841A JP2019509055A5 JP 2019509055 A5 JP2019509055 A5 JP 2019509055A5 JP 2018555841 A JP2018555841 A JP 2018555841A JP 2018555841 A JP2018555841 A JP 2018555841A JP 2019509055 A5 JP2019509055 A5 JP 2019509055A5
Authority
JP
Japan
Prior art keywords
cancer
miac
abm2
abm3
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018555841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509055A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/013512 external-priority patent/WO2017124002A1/en
Publication of JP2019509055A publication Critical patent/JP2019509055A/ja
Publication of JP2019509055A5 publication Critical patent/JP2019509055A5/ja
Withdrawn legal-status Critical Current

Links

JP2018555841A 2016-01-13 2017-01-13 多特異性免疫調節抗原結合構築物 Withdrawn JP2019509055A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662278359P 2016-01-13 2016-01-13
US62/278,359 2016-01-13
US201662361842P 2016-07-13 2016-07-13
US62/361,842 2016-07-13
PCT/US2017/013512 WO2017124002A1 (en) 2016-01-13 2017-01-13 Multispecific immunomodulatory antigen-binding constructs

Publications (2)

Publication Number Publication Date
JP2019509055A JP2019509055A (ja) 2019-04-04
JP2019509055A5 true JP2019509055A5 (enExample) 2020-02-27

Family

ID=59311459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018555841A Withdrawn JP2019509055A (ja) 2016-01-13 2017-01-13 多特異性免疫調節抗原結合構築物

Country Status (9)

Country Link
US (1) US20190031785A1 (enExample)
EP (1) EP3402519A4 (enExample)
JP (1) JP2019509055A (enExample)
CN (1) CN109562162A (enExample)
AU (1) AU2017207480A1 (enExample)
BR (1) BR112018014368A2 (enExample)
CA (1) CA3011535A1 (enExample)
MA (1) MA43874A (enExample)
WO (1) WO2017124002A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180318417A1 (en) * 2015-01-14 2018-11-08 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP4491234A3 (en) * 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
BR112020000719A2 (pt) 2017-07-11 2020-07-14 Compass Therapeutics Llc anticorpos agonistas que ligam o cd137 humano e seus usos
IL311488A (en) * 2017-08-23 2024-05-01 Dragonfly Therapeutics Inc Proteins that bind D2NKG, 16CD, and tumor-associated antigen
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3740505A1 (en) * 2018-01-16 2020-11-25 Lakepharma Inc. Bispecific antibody that binds cd3 and another target
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
EP3759146A1 (en) * 2018-03-02 2021-01-06 CDR-Life AG Trispecific antigen binding proteins
MX2020012273A (es) * 2018-05-16 2021-04-28 Dragonfly Therapeutics Inc Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos.
EP3797120A1 (en) * 2018-05-21 2021-03-31 Compass Therapeutics LLC Compositions and methods for enhancing the killing of target cells by nk cells
KR20250151605A (ko) 2018-06-01 2025-10-21 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
BR112021008795A2 (pt) 2018-11-13 2021-08-31 Compass Therapeutics Llc Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos
US20220213193A1 (en) * 2019-05-06 2022-07-07 Brown University Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
KR20220010743A (ko) 2019-05-21 2022-01-26 노파르티스 아게 Bcma에 대한 삼중특이적 결합 분자 및 이의 용도
CN112409484B (zh) * 2019-08-22 2023-03-21 盛禾(中国)生物制药有限公司 多功能抗体、其制备及其用途
TWI888487B (zh) * 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
US20230357793A1 (en) * 2020-06-26 2023-11-09 Sorrento Therapeutics, Inc. Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
AR123767A1 (es) 2020-10-13 2023-01-11 Janssen Biotech Inc Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii
WO2022097061A1 (en) 2020-11-06 2022-05-12 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
CN114736291B (zh) * 2021-01-07 2023-08-11 中国科学院微生物研究所 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
WO2022200478A1 (en) * 2021-03-24 2022-09-29 Pieris Pharmaceuticals Gmbh Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
CN117836328A (zh) * 2021-06-15 2024-04-05 盛禾(中国)生物制药有限公司 一种多特异性抗原结合蛋白及其应用
JP2024529381A (ja) * 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
WO2023011268A1 (zh) * 2021-08-02 2023-02-09 盛禾(中国)生物制药有限公司 一种多特异性抗原结合蛋白及其应用
WO2023192973A1 (en) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
ES2637801T3 (es) * 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
WO2009018386A1 (en) * 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
AU2012245116A1 (en) * 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
EP2760892A1 (en) * 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
CN104185642A (zh) * 2011-12-27 2014-12-03 财团法人生物技术开发中心 轻链桥连的双特异性抗体
US20180318417A1 (en) * 2015-01-14 2018-11-08 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs

Similar Documents

Publication Publication Date Title
JP2019509055A5 (enExample)
CN110914306B (zh) 检查点抑制物双特异性抗体
RU2445319C2 (ru) Моноклональные антитела к клаудину-18 для лечения рака
ES2776706T3 (es) Anticuerpos contra CD3 humanizados o quiméricos
JP2018503399A5 (enExample)
US11913025B2 (en) Antigen-specific T cells and uses thereof
IL273424B1 (en) Novel bispecific cd3/cd19 polypeptide complexes
JP2020500540A5 (enExample)
JP2025023994A (ja) バイパラトピックＦＲ－α抗体及びイムノコンジュゲート
EP3774921A1 (en) Antibody variable domains targeting dll3, and use thereof
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2018507188A5 (enExample)
JP2013502913A5 (enExample)
EP3177646A1 (en) Cd3 binding domain
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2013545455A5 (enExample)
CN106414494A (zh) 具有促凋亡活性的人IgG1衍生的抗体
JP2025186381A (ja) Ｃｄ１３７結合分子及びその使用
JP2023501379A (ja) ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
TW201927819A (zh) 雙專一性抗體及製造與使用其的方法
US20250188166A1 (en) Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
JP7730432B2 (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
US20220204644A1 (en) Combination of her2 antibodies
JPWO2021068841A5 (enExample)
US20260055173A1 (en) Bispecific antibody and application thereof